Get the Stockscreener App
4.62
0.65%
0.03
After Hours:
4.62
Cytek Biosciences Inc stock is traded at $4.62, with a volume of 1.05M.
It is up +0.65% in the last 24 hours and up +12.96% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$4.59
Open:
$4.56
24h Volume:
1.05M
Relative Volume:
0.82
Market Cap:
$596.64M
Revenue:
$204.17M
Net Income/Loss:
$-74.00M
P/E Ratio:
-8.00
EPS:
-0.5775
Net Cash Flow:
$-12.84M
1W Performance:
+6.45%
1M Performance:
+12.96%
6M Performance:
-16.30%
1Y Performance:
+22.87%
1-Day Range:
$4.495
$4.735
1-Week Range:
$4.26
$4.735
52-Week Range:
$3.09
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.62 | 572.10M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences (NASDAQ: CTKB) adds Chief Legal Officer as reporting insider - Stock Titan
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from Russell 2000 Defensive Index - marketscreener.com
Enterprise value to revenue forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to earnings forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Enterprise value to EBIT forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to sales forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Enterprise value to revenue forward of Cytek Biosciences, Inc. – BOATS:CTKB - TradingView
CTKB Forecast — Price Target — Prediction for 2027 - TradingView
8EQ Forecast — Price Target — Prediction for 2027 - TradingView
Cytek Biosciences, Inc. Actuals & Estimates (NASDAQ:CTKB) - TradingView
Cytek Biosciences, Inc. Actuals & Estimates (GETTEX:8EQ) - TradingView
Cytek Biosciences Announces Chief Legal Officer Transition - TipRanks
Cytek Biosciences' Valerie Barnett to Depart as Chief Legal Officer and Corporate Secretary - TradingView
Cytek Biosciences (NASDAQ: CTKB) legal chief exit detailed - Stock Titan
Cytek Biosciences, Inc. Announces Termination of Valerie Barnett as Chief Legal Officer and Corporate Secretary, Effective June 29, 2026 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 1000 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 Health Care - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P Composite 1500 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 - marketscreener.com
Cytek Biosciences Inc (CTKB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytek Biosciences Stockholders Back Board, Pay and Auditor - The Globe and Mail
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets - Yahoo Finance
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytek Biosciences Inc (CTKB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting By Investing.com - Investing.com South Africa
Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting - Investing.com Canada
Cytek Biosciences launches quick reference guide to streamline lab use of cFluor dyes - Traders Union
Cytek Biosciences Inc (CTKB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytek Biosciences (CTKB) CTO Yan Ming reports bona fide gift of shares - Stock Titan
Cytek Biosciences Inc (CTKB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytek Biosciences (CTKB) details 2026 shareholder meeting voting outcomes - Stock Titan
Cytek Biosciences Inc (CTKB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytek Biosciences Inc (CTKB) Institutional Confidence - TradingKey
Cytek Biosciences (CTKB) Singular Research’s Las Vegas Invitational Conference summary - Quartr
Cytek Biosciences, Inc. (CTKB) Presents at Singular Research's Las Vegas Invitational ConferenceSlideshow - Seeking Alpha
Cytek Biosciences (CTKB) director converts 43,973 RSUs to common stock - Stock Titan
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity - Stock Titan
Cytek Biosciences (CTKB) director Glenn Muir files initial ownership report - Stock Titan
Cytek Biosciences (CTKB) director awarded 18,261 options plus 33,333 RSUs - Stock Titan
Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants - Stock Titan
Cytek Biosciences (CTKB) director exercises RSUs and receives new equity awards - Stock Titan
Cytek Biosciences (CTKB) director exercises 43,973 RSUs, granted options and RSUs - Stock Titan
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference - GlobeNewswire
Cytek Biosciences debuts Borealis spectral cytometer - Select Science
Cytek Biosciences Shares Fall After Borealis News and Sales Exit - Bez Kabli
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 - BioSpace
Cytek Biosciences Announces Resignation of Senior Sales Executive - TipRanks
Cytek Biosciences' Philippe Busque resigns as Senior VP, Global Sales and Services - TradingView
Cytek Biosciences, Inc. Announces Resignation of Philippe Busque from Senior Vice President, Global Sales and Services, Effective June 5, 2026 - marketscreener.com
Cytek Biosciences (CTKB) SVP Global Sales and Services to step down June 5, 2026 - Stock Titan
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):